NEW YORK, Oct. 5 (GenomeWeb News) - Rubicon Genomics has granted Sigma-Aldrich an exclusive, worldwide license to GenomePlex, Rubicon's whole-genome amplification technology, the companies said today.
Under the terms of the agreement, Sigma-Aldrich will have exclusive world-wide rights to produce and sell GenomePlex kits to the research market. Rubicon, based in Ann Arbor, Mich., will retain all rights to the technology for its core market - molecular diagnostics - as well as for service, the companies said.
Financial details of the agreement were not disclosed.
Rubicon said that GenomePlex amplifies total human DNA at the sub-nanogram level by using random, non-enzymatic fragmentation of genomic DNA followed by the addition of specific adaptor sequences to both ends, forming an in vitro molecular library that can be amplified with conventional techniques.